表紙
市場調查報告書
商品編碼
990064

肱骨外上髁炎治療的全球市場:2021年∼2025年

Global Lateral Epicondylitis Treatment Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球肱骨外上髁炎治療的市場規模在2021年∼2025年間,預測將成長到19億1000萬美元,在預測期間內預計將以4%的年複合成長率增長。

市場成長的主要因素有>對肱骨外上髁炎的認識不斷提高,肱骨外上髁炎的危險因素日益普及。

這份報告提供肱骨外上髁炎治療的全球市場的整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2020年的市場規模
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

市場區隔:各類型

  • 市場區隔
  • 各類型比較
  • 非外科治療:市場規模與預測(2020年∼2025年)
  • 外科治療:市場規模與預測(2020年∼2025年)
  • 各類型的市場機會

客戶形勢

  • 客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 各地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 競爭模式
  • 業者情勢
  • 創造性破壞狀況
  • 產業的風險

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • 3M Co.
  • Bayer AG
  • Cipla Inc.
  • Colfax Corp.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR70076

Technavio has been monitoring the lateral epicondylitis treatment market and it is poised to grow by $ 1.91 bn during 2021-2025 progressing at a CAGR of 4% during the forecast period. Our report on lateral epicondylitis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising awareness about lateral epicondylitis, growing prevalence of risk factors for lateral epicondylitis. In addition, rising awareness about lateral epicondylitis is anticipated to boost the growth of the market as well.

The lateral epicondylitis treatment market analysis includes type segment and geographical landscapes.

Technavio's lateral epicondylitis treatment market is segmented as below:

By Type

  • Non-surgical treatment
  • Surgical treatment

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high incidence of sports injuries as one of the prime reasons driving the lateral epicondylitis treatment market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on lateral epicondylitis treatment market covers the following areas:

  • Lateral epicondylitis treatment market sizing
  • Lateral epicondylitis treatment market forecast
  • Lateral epicondylitis treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lateral epicondylitis treatment market vendors that include 3M Co., Bayer AG, Cipla Inc., Colfax Corp., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Sun Pharmaceutical Industries Ltd.. Also, the lateral epicondylitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Non-surgical treatment - Market size and forecast 2020-2025
  • Surgical treatment - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer landscape

  • Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive scenario
  • Vendor landscape
  • Landscape disruption
  • Industry risks

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Bayer AG
  • Cipla Inc.
  • Colfax Corp.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Non-surgical treatment - Market size and forecast 2020-2025 ($ million)
  • 24: Non-surgical treatment - Year-over-year growth 2020-2025 (%)
  • 25: Surgical treatment - Market size and forecast 2020-2025 ($ million)
  • 26: Surgical treatment - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: 3M Co. - Overview
  • 48: 3M Co. - Business segments
  • 49: 3M Co. - Key offerings
  • 50: 3M Co. - Key customers
  • 51: 3M Co. - Segment focus
  • 52: Bayer AG - Overview
  • 53: Bayer AG - Business segments
  • 54: Bayer AG - Key offerings
  • 55: Bayer AG - Key customers
  • 56: Bayer AG - Segment focus
  • 57: Cipla Inc. - Overview
  • 58: Cipla Inc. - Business segments
  • 59: Cipla Inc. - Key offerings
  • 60: Cipla Inc. - Key customers
  • 61: Cipla Inc. - Segment focus
  • 62: Colfax Corp. - Overview
  • 63: Colfax Corp. - Business segments
  • 64: Colfax Corp. - Key offerings
  • 65: Colfax Corp. - Key customers
  • 66: Colfax Corp. - Segment focus
  • 67: GlaxoSmithKline Plc - Overview
  • 68: GlaxoSmithKline Plc - Business segments
  • 69: GlaxoSmithKline Plc - Key offerings
  • 70: GlaxoSmithKline Plc - Key customers
  • 71: GlaxoSmithKline Plc - Segment focus
  • 72: Johnson & Johnson - Overview
  • 73: Johnson & Johnson - Business segments
  • 74: Johnson & Johnson - Key offerings
  • 75: Johnson & Johnson - Key customers
  • 76: Johnson & Johnson - Segment focus
  • 77: Merck & Co. Inc. - Overview
  • 78: Merck & Co. Inc. - Business segments
  • 79: Merck & Co. Inc. - Key offerings
  • 80: Merck & Co. Inc. - Key customers
  • 81: Merck & Co. Inc. - Segment focus
  • 82: Perrigo Co. Plc - Overview
  • 83: Perrigo Co. Plc - Business segments
  • 84: Perrigo Co. Plc - Key offerings
  • 85: Perrigo Co. Plc - Key customers
  • 86: Perrigo Co. Plc - Segment focus
  • 87: Pfizer Inc. - Overview
  • 88: Pfizer Inc. - Business segments
  • 89: Pfizer Inc. - Key offerings
  • 90: Pfizer Inc. - Key customers
  • 91: Pfizer Inc. - Segment focus
  • 92: Sun Pharmaceutical Industries Ltd. - Overview
  • 93: Sun Pharmaceutical Industries Ltd. - Business segments
  • 94: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 95: Sun Pharmaceutical Industries Ltd. - Key customers
  • 96: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations